The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Daratumumab in the treatment of high-risk MGUS and low-risk smoldering myeloma
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses two ongoing Phase II clinical trials: one investigating the use of daratumumab in high-risk monoclonal gammopathy of undetermined significance (MGUS) and low-risk smoldering multiple myeloma (SMM), and the other investigating ixazomib, lenalidomide and dexamethasone in high-risk SMM. Dr Ghobrial explains the main aims of these trials, which is to investigate the safety and efficacy of daratumumab in low-risk SMM, as well as look for new methods to prevent patients with low-risk smoldering myeloma from entering the high-risk category. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
